The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment
SK Kim, SW Cho - Frontiers in pharmacology, 2022 - frontiersin.org
Recently, in the field of cancer treatment, the paradigm has changed to immunotherapy that
activates the immune system to induce cancer attacks. Among them, immune checkpoint …
activates the immune system to induce cancer attacks. Among them, immune checkpoint …
Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications
Tumor heterogeneity is a hallmark of cancer and one of the primary causes of resistance to
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
The FUS/circEZH2/KLF5/feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition
P Liu, Z Wang, X Ou, P Wu, Y Zhang, S Wu, X Xiao… - Molecular cancer, 2022 - Springer
Background Metastasis of breast cancer have caused the majority of cancer-related death
worldwide. The circRNAs are associated with tumorigenesis and metastasis in breast cancer …
worldwide. The circRNAs are associated with tumorigenesis and metastasis in breast cancer …
LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression
T Sun, Z Wu, X Wang, Y Wang, X Hu, W Qin, S Lu, D Xu… - Oncogene, 2020 - nature.com
Increasing evidence supports that long noncoding RNAs (lncRNAs) act as master regulators
involved in tumorigenesis and development at the N 6-methyladenine (m6A) epigenetic …
involved in tumorigenesis and development at the N 6-methyladenine (m6A) epigenetic …
The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis
KA Zielińska, VL Katanaev - Cancers, 2020 - mdpi.com
Simple Summary Breast cancer remains the most common malignancy in women. In this
review, we explore the role of the CXCL12/CXCR4 pathway in breast cancer. We show that …
review, we explore the role of the CXCL12/CXCR4 pathway in breast cancer. We show that …
Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials
Epidemiological evidence shows that diabetic patients have an increased cancer risk and a
higher mortality rate. Glucose could play a central role in metabolism and growth of many …
higher mortality rate. Glucose could play a central role in metabolism and growth of many …
Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease?
P Busek, JS Duke-Cohan, A Sedo - Cancers, 2022 - mdpi.com
Simple Summary There is growing interest in identifying the effects of antidiabetic agents on
cancer risk, progression, and anti-cancer treatment due to the long-term use of these …
cancer risk, progression, and anti-cancer treatment due to the long-term use of these …
Cancer biology and prevention in diabetes
SP Srivastava, JE Goodwin - Cells, 2020 - mdpi.com
The available evidence suggests a complex relationship between diabetes and cancer.
Epidemiological data suggest a positive correlation, however, in certain types of cancer, a …
Epidemiological data suggest a positive correlation, however, in certain types of cancer, a …
The CXCL12/CXCR4/ACKR3 axis in the tumor microenvironment: signaling, crosstalk, and therapeutic targeting
Elevated expression of the chemokine receptors CXCR4 and ACKR3 and of their cognate
ligand CXCL12 is detected in a wide range of tumors and the tumor microenvironment …
ligand CXCL12 is detected in a wide range of tumors and the tumor microenvironment …
Biomimetic nanomedicine coupled with neoadjuvant chemotherapy to suppress breast cancer metastasis via tumor microenvironment remodeling
The biomimetic enzyme activity of cerium oxide nanoparticles (CeNPs) prefers ultrasmall
particle size and bare surface. Unfortunately, those two features are not favorable for its in …
particle size and bare surface. Unfortunately, those two features are not favorable for its in …